0ADL Stock Chart & Stats
$73.76
-$4.20(-6.71%)
At close: 4:00 PM EDT
$73.76
-$4.20(-6.71%)
Day’s Range― - ―
52-Week Range$58.40 - $88.26
Previous CloseN/A
Volume10.00
Average Volume (3M)58.00
Market Cap
$32.12B
Enterprise Value$37.74B
Total Cash (Recent Filing)$2.10B
Total Debt (Recent Filing)$10.09B
Price to Earnings (P/E)20.4
Beta0.55
Next Earnings
Feb 10, 2027EPS Estimate
1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.48
Shares OutstandingN/A
10 Day Avg. Volume102
30 Day Avg. Volume58
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda12.28
Forecast
1Y Price Target
$80.20Price Target Upside8.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)4.92
Revenue Forecast (FY)$21.72B
Bulls Say, Bears Say
Bulls Say
Recurring And Diversified Revenue ModelGEHC combines less-frequent capital equipment sales with recurring service contracts and repeat-use diagnostic consumables. This mix links revenue to both installed-base support and ongoing procedure volumes, providing greater durability than reliance on equipment purchases alone.
Strong Orders, Backlog, And Operating MomentumBroad-based organic growth, margin expansion, and a 12% year-over-year backlog increase indicate sustained customer demand and improving execution. The sizeable backlog supports forward revenue visibility, while stronger profitability and raised guidance suggest operating momentum can persist over coming quarters.
Pharmaceutical Diagnostics Growth And InnovationPharmaceutical Diagnostics is a clear growth engine, supported by contrast media, radiopharmaceuticals, and demand for precision medicine. Repeated high single-digit expansion and a growing innovation pipeline can increase GEHC’s exposure to recurring procedure-driven markets over time.
Bears Say
Profitability And Free Cash Flow PressureAlthough GEHC remains profitable, lower net and operating margins indicate that stronger revenue is not fully translating into earnings. The sharp free-cash-flow decline further limits internally funded investment, debt reduction, and shareholder returns if the weaker conversion persists.
Meaningful Leverage RemainsLeverage has improved and equity has rebuilt, but debt remains roughly equal to equity. This capital structure can constrain financial flexibility and make interest, refinancing, and capital-allocation decisions more consequential if earnings or cash generation weaken.
Patient Care Solutions Execution RiskPCS has improved backlog conversion and operating performance, but unresolved parts, supplier, capacity, and customer-site issues remain. Continued recovery work could delay fulfillment, restrain segment growth, and prevent recent margin gains from becoming fully durable.
GE Healthcare Technologies Inc News
0ADL FAQ
What was GE Healthcare Technologies Inc’s price range in the past 12 months?
GE Healthcare Technologies Inc lowest share price was $58.40 and its highest was $88.26 in the past 12 months.
What is GE Healthcare Technologies Inc’s market cap?
GE Healthcare Technologies Inc’s market cap is $32.12B.
When is GE Healthcare Technologies Inc’s upcoming earnings report date?
GE Healthcare Technologies Inc’s upcoming earnings report date is Feb 10, 2027 which is in 105 days.
How were GE Healthcare Technologies Inc’s earnings last quarter?
GE Healthcare Technologies Inc released its earnings results on Oct 28, 2026. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.204 by $0.136.
Is GE Healthcare Technologies Inc overvalued?
According to Wall Street analysts GE Healthcare Technologies Inc’s price is currently Undervalued.
Does GE Healthcare Technologies Inc pay dividends?
GE Healthcare Technologies Inc does not currently pay dividends.
What is GE Healthcare Technologies Inc’s EPS estimate?
GE Healthcare Technologies Inc’s EPS estimate is 1.6.
How many shares outstanding does GE Healthcare Technologies Inc have?
Currently, no data Available
What happened to GE Healthcare Technologies Inc’s price movement after its last earnings report?
GE Healthcare Technologies Inc reported an EPS of $1.34 in its last earnings report, beating expectations of $1.204. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GE Healthcare Technologies Inc?
Currently, no hedge funds are holding shares in GB:0ADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GE Healthcare Technologies Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$80.20 (8.73% Upside)
$80.20 (8.73% Upside)
Blogger Sentiment
Bullish
GB:0ADL Sentiment 88%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.05%
12-Months-Change
Fundamentals
Return on Equity
15.16%
Trailing 12-Months
Asset Growth
4.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GE Healthcare Technologies Inc
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
0ADL Company Deck
0ADL Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Highlights significantly outweighed the lowlights, with strong organic revenue growth, broad-based segment performance, margin and EPS expansion, higher free cash flow, raised full-year guidance, regulatory progress, expanding radiopharmaceutical adoption, and confidence in the 2027 and 2028 outlook. The company acknowledged inflation, tariff uncertainty, PCS recovery work, China execution challenges, and generic competition, but management described mitigation actions and maintained confidence in the business trajectory.View all GB:0ADL earnings summaries0ADL Revenue Breakdown
44.82% Imaging
25.96% AVS
14.96% PCS
14.06% PDx
0.19% Other
0ADL Stock 12 Month Forecast
Average Price Target
$80.20
▲(8.73% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Koninklijke Philips
―
Medtronic
―